Cargando…
Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis
The third-generation aromatase inhibitors (AIs: anastrozole, letrozole, and exemestane) have now become standard adjuvant endocrine treatment for postmenopausal estrogen receptor-positive breast cancer complementing chemotherapy and surgery. Because of the absence of direct head-to-head comparisons...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599049/ https://www.ncbi.nlm.nih.gov/pubmed/26491345 http://dx.doi.org/10.2147/OTT.S88179 |